Quantinno Capital Management LP Grows Position in Progyny, Inc. $PGNY

Quantinno Capital Management LP boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 382.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,251 shares of the company’s stock after buying an additional 114,358 shares during the quarter. Quantinno Capital Management LP owned 0.18% of Progyny worth $2,449,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the last quarter. Amundi raised its holdings in shares of Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after purchasing an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Invesco Ltd. lifted its position in Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the period. Finally, Walleye Capital LLC boosted its holdings in Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after purchasing an additional 780 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Price Performance

Shares of Progyny stock opened at $28.10 on Monday. The company’s fifty day simple moving average is $29.08 and its 200-day simple moving average is $23.42. The stock has a market capitalization of $2.20 billion, a PE ratio of 30.54, a P/E/G ratio of 2.23 and a beta of 1.01. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $33.06.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.26 by $0.24. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The firm had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.46 million. During the same period in the prior year, the business posted $0.17 EPS. Progyny’s revenue was down 26.4% on a year-over-year basis. As a group, research analysts anticipate that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Progyny

In other news, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the transaction, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at $1,904,544. The trade was a 3.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,916 shares of company stock valued at $939,875 in the last ninety days. 9.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on PGNY. Truist Financial lifted their target price on shares of Progyny from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. BTIG Research raised their price target on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Bank of America upped their price objective on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.20.

More Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter earnings of $0.55 per share, well above the $0.33 consensus estimate, while revenue of $350.5 million modestly exceeded expectations of $348.6 million. Revenue increased 5.3% year over year, and earnings improved from $0.19 per share in the prior-year quarter. Progyny Announces Second Quarter 2026 Results
• Positive Sentiment: Full-year 2026 adjusted EPS guidance of $2.04 to $2.10 is above the analyst consensus of $1.86, signaling confidence in profitability. Full-year revenue guidance of approximately $1.4 billion is broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: CEO Pete Anevski is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 11. The event could provide additional detail on client demand, growth initiatives and the company’s outlook, but it does not immediately change financial results. Progyny to Present at Canaccord Genuity Conference
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million is below the $350.2 million analyst consensus. Although projected EPS of $0.50 to $0.52 exceeds the $0.47 consensus, investors appear more concerned about slower top-line momentum and the possibility that growth remains muted. Why Progyny Shares Are Sliding Today

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.